IRIS
GROSSI, Laurino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.711
EU - Europa 5.274
AS - Asia 5.073
SA - Sud America 528
AF - Africa 54
Continente sconosciuto - Info sul continente non disponibili 22
OC - Oceania 6
Totale 18.668
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.606
SG - Singapore 1.943
CN - Cina 1.465
IT - Italia 854
UA - Ucraina 821
IE - Irlanda 729
TR - Turchia 582
RU - Federazione Russa 578
SE - Svezia 565
GB - Regno Unito 540
FR - Francia 431
BR - Brasile 422
VN - Vietnam 402
IN - India 379
DE - Germania 320
FI - Finlandia 180
BD - Bangladesh 75
AT - Austria 65
PL - Polonia 56
CA - Canada 53
HK - Hong Kong 44
MX - Messico 38
AR - Argentina 36
IQ - Iraq 33
NL - Olanda 29
EC - Ecuador 27
JP - Giappone 21
KR - Corea 21
EU - Europa 20
BE - Belgio 18
ZA - Sudafrica 17
ES - Italia 16
ID - Indonesia 16
RO - Romania 16
CO - Colombia 11
LT - Lituania 11
MA - Marocco 11
PK - Pakistan 11
IL - Israele 10
CL - Cile 8
JO - Giordania 8
KE - Kenya 8
UZ - Uzbekistan 8
AE - Emirati Arabi Uniti 7
PE - Perù 7
PY - Paraguay 7
SA - Arabia Saudita 7
CZ - Repubblica Ceca 6
GR - Grecia 6
AU - Australia 5
CH - Svizzera 5
PS - Palestinian Territory 5
TW - Taiwan 5
AL - Albania 4
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
DZ - Algeria 4
EG - Egitto 4
IR - Iran 4
PH - Filippine 4
VE - Venezuela 4
EE - Estonia 3
ET - Etiopia 3
HU - Ungheria 3
JM - Giamaica 3
MY - Malesia 3
NO - Norvegia 3
OM - Oman 3
UY - Uruguay 3
BG - Bulgaria 2
BH - Bahrain 2
BO - Bolivia 2
CI - Costa d'Avorio 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
KZ - Kazakistan 2
LB - Libano 2
LU - Lussemburgo 2
PA - Panama 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AP - ???statistics.table.value.countryCode.AP??? 1
BB - Barbados 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CG - Congo 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
KH - Cambogia 1
LV - Lettonia 1
MD - Moldavia 1
MU - Mauritius 1
NI - Nicaragua 1
NP - Nepal 1
PT - Portogallo 1
PW - Palau 1
RE - Reunion 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
Totale 18.663
Salva come PNG Salva come JPEG
Città #
Singapore 1.306
Jacksonville 944
San Jose 815
Chandler 779
Dublin 721
Dearborn 468
Ashburn 399
Southend 378
Princeton 354
Beijing 335
Dallas 312
Nanjing 284
Izmir 272
Council Bluffs 256
Wilmington 254
Los Angeles 211
Cambridge 157
Ho Chi Minh City 130
Buffalo 121
Woodbridge 119
Santa Clara 116
Ann Arbor 115
New York 108
Tongling 104
Nanchang 93
The Dalles 93
Hanoi 88
Boardman 66
Houston 66
Moscow 57
Hefei 56
Hebei 53
Vienna 52
Shenyang 48
Altamura 47
Munich 47
Rome 47
São Paulo 47
Redondo Beach 46
Kunming 45
Tianjin 43
Jiaxing 40
Kraków 35
Pescara 35
Hong Kong 34
Chieti 29
Hangzhou 29
Bologna 26
Brooklyn 26
Norwalk 25
Da Nang 24
Milan 23
Dong Ket 22
Haiphong 22
Düsseldorf 20
Jinan 20
Changsha 19
Tokyo 19
Ancona 18
Chicago 18
Frankfurt am Main 18
Orange 18
Warsaw 18
Brussels 17
Seoul 17
Baghdad 16
Belo Horizonte 16
Guangzhou 16
Helsinki 16
Montreal 16
Washington 16
Bellante 15
Boston 15
Denver 15
Guayaquil 15
Turku 15
Amsterdam 14
Grevenbroich 14
Lanzhou 14
Orem 14
Phoenix 14
Vinh 14
Ankara 13
London 13
Nuremberg 13
Seattle 13
Atlanta 12
Mumbai 12
Charlotte 11
Fuzhou 11
San Francisco 11
Stockholm 11
Toronto 11
Falls Church 10
Guadalajara 10
Johannesburg 10
Poplar 10
Rio de Janeiro 10
Brasília 9
Cepagatti 9
Totale 11.078
Salva come PNG Salva come JPEG
Nome #
Il tempo di transito oro-cecale (TTOC) è accelerato dopo somministrazione orale di allergene alimentare nei pazienti con sindrome del colon irritabile (SCI) e prick test positivo 404
EFFICACY OF TREATMENT WITH PYLERA IN COMBINATION WITH RANITIDINE ON FIRST-LINE INFECTION HELICOBACTER PYLORI: EXPERIENCE OF A SINGLE CENTER 299
A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study 189
Ottimizzazione di vedolizumab in RCU con perdita di risposta a infliximab 175
48-Hour continuous pH measurement in patients with gastro-oesophageal reflux: effect of cisapride. 172
Beneficial effects of SR140333, a novel substance P antagonist, in a rat model of experimental colitis 171
Blood cardioplegia: could it protect the ischemic-reperfused human myocardium through antioxidant-type mechanisms? 168
SYMPTOM PATTERN IN FUNCTIONAL DYSPEPSIA AND GASTROESOPHAGEAL REFLUX DISEASE: ROLE OF H. PYLORI INFECTION 168
Alterazioni non litiasiche del contenuto colecistico 164
24-hour pancolonic motility using a portable electronic probe in healthy subjects 162
In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy 162
Detection of Helicobacter pylori in the gastrointestinal tract of Balb/C euthymic mice infected by human Helicobacter pylori and evidence for transmission 155
SR140333, a substance P receptor antagonist, influences morphological and motor changes in rat experimental colitis 154
Anti-Helicobacter pylori specific antibody immunohistochemistry improves the diagnostic accuracy of Helicobacter pylori in biopsy specimen from patients treated with triple therapy.Am. J. Gastroenterol 151
Two weeks regimen with amoxillicin, tinidazole and omeprazole eradicates helicobacter pylori and cures active duodenal ulcer 149
Anal canal diameters and pessure measured simultaneously by real time ultrasonography and manometry in human subjects 147
Alterazioni contrattili della muscolatura liscia nel corso di colite sperimentale sono ridotte da un antagonista specifico della sostanza P 145
FUSOBACTERIUM NUCLEATUM (FN) IN PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE 141
Trasmissione di Helicobacter pylori in un modello murino 140
COMBINED VIDEOCAPSULE ENDOSCOPY (VCE) AND LACTULOSE HYDROGEN BREATH TEST (LHBT): A COMPARATIVE STUDY TO ASSESS ORO-CECAL TRANSIT TIME (OCTT). 140
Correlation between anal canal size and anal canal pressure: an ultrasonografhip and manometric study 139
EVALUATION OF INTRAPARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND LIVER STIFFNESS BY FIBROSCAN IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CHRONIC HEPATITIS C (CHC) 137
Diameters and pressures of the anal canal simultaneously measured with endosonography and manometry 136
THE INFLUENCE OF ACID REFLUX ON THE HEART RATE VARIABILITY (HRV) IN PATIENTS WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE (GERD) 136
Helicobacter pylori isolates from proximal and distal stomach of patients never treated and already treated show genetic variability and discordant antibiotic resistance. 135
THE INFLUENCE OF ACID REFLUX ON THE HEART RATE VARIABILITY (HRV) IN PATIENTS WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE (GERD). 134
Gastric antral and fundus receptive relaxation in dyspeptic patients and normal subjects 133
Effect of omeprazole, clarithromicin and amoxicillin for a short time on helicobacter pylori eradication 133
ESOPHAGITIS AND ITS CAUSES: WHO IS "GUILTY" WHEN ACID IS FOUND "NOT GUILTY"? 133
EVALUATION OF INTRAPARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND LIVER STIFFNESS BY FIBROSCAN IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CHRONIC HEPATITIS C (CHC). 132
PRUCALOPRIDE ACCELERATES GASTRIC AND SMALL BOWEL TRANSIT TIMES OF VIDEOCAPSULES ENDOSCOPY 130
Distribuzione transmurale dei sistemi antiossidanti e della perossidazione lipidica nel ventricolo sinistro di coniglio 129
ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: THE ELDERLY COHORT 128
Prolonged anal sphincter manometry in normal human subjects 127
Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. 127
Morphological and motor changes during experimental colits in rats are prevented by a specific substance p antagonist 127
Pharyngeal, Esophageal and Gastric Motility in Normal Subjects and in patients with gastroesophageal Reflux Disease 125
Short- and long-term omeplazole for the tratment and prevention of duodenal ulcer, and effect on helicobacter pylori 125
A “REAL LIVE” EXPERIENCE OF INFLIXIMAB USE FOR CROHN’S DISEASE IN SOUTHERN ITALY 125
Treatment of Helicobacter pylori (Hp) infection with an association of Omeprazole and Roxytromicine: a study in vivo and in vitro. 125
MIGRATING MOTOR COMPLEX RECORDED SPONTANEOUSLY AND INDUCED BY MOTILIN AND ERYTHROMYCIN IN AN EX VIVO RABBIT INTESTINAL PREPARATION 124
Detection of Helicobacter pylori in esophagus and saliva in humans 123
H2-RECEPTOR ANTAGONISTS ARE SCAVENGERS OF OXYGEN RADICALS 122
5-HT1-RECEPTOR AGONIST SUMATRIPTAN MODIFIES GASTRIC SIZE AFTER 500 ML OF WATER IN DYSPEPTIC PATIENTS AND NORMAL SUBJECTS 122
USO DI GOLIMUMAB COME SECONDA LINEA BIOLOGICA IN UN PAZIENTE CON RETTOCOLITE ULCEROSA 122
Swallows, oesophageal and gastric motility in normal subjects and in patients with gastro-oesophageal reflux disease: a 24-h-pH-manometric study 121
REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE (IG-IBD). 121
Erythromycin accellerates gastric and gallbladder emptying through a cholinergic mediated mechanism in humans 120
Oesophageal and gastric motility in patients with gastro-oesophageal reflux disease 118
CAN HELICOBACTER PYLORI INFECTION HAVE A ROLE ON CLINICAL APPEARANCE OF GERD? 118
Effects of cimetropium bromide on gallbladder contraction in response to oral and intraduodenal olive oil. 118
Transmission of Helicobacter pylori in an animal model. 117
EVALUATION OF LIVER BLOOD FLOW AND FIBROSIS IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CIRRHOSIS IN COMPARISON WITH NORMAL CONTROLS THROUGH CONTRAST ENHANCED ULTRASOUND(CEUS) AND FIBROSCAN 117
Evidence for an oro-fecal transmission inan experimental murine model of helicobacter pylori infection. 116
TYPICAL AND ATYPICAL SYMPTOMS OF GASTRO ESOPHAGEAL REFLUX DISEASE: DOES Helicobacter pylori MATTER? 116
Influence of the COVID-19 Outbreak on Disease Activity and Quality of Life in Inflammatory Bowel Disease Patients 116
EFFICACY AND SAFETY OF LONG-TERM INFLIXIMAB USE FOR CROHN’S DISEASE IN SOUTHERN ITALY 115
PRUCALOPRIDE INCREASES BASAL LES TONE IN PATIENTS WITH ESOPHAGEAL MOTILITY DISORDERS 115
Effect of omeprazole, clarithromicin and amoxicillin for a short time on helicobacter pylori eradication 114
Peppermint oil (Mintoil®) in the treatment or irritable bowel syndrome: a prospective double blind placebo controlled randomized trial. 114
CLINICAL AND ECONOMIC IMPACT OF INFLIXIMAB ONE-HOUR INFUSION PROTOCOL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY 113
EFFECT OF CIMETROPIUM BROMIDE ON GALLBLADDER CONTRACTION IN RESPONSE TO ORAL AND INTRADUODENAL OLIVE OIL 112
Esophageal and gastric motility in patients with gastroesophageal reflux disease 111
Distensione gastrica nei soggetti normali e nei pazienti dispeptici helicobacter pylori positivi e negativi e correlazione con i sintomi 111
Role of transient lower esophageal sphincter relaxations in the genesis of priximal gastro-esophageal reflux 111
Effect of glyceryl trinitrate ointment (GTO) 0.2% and 2% on anal canal pressure during acute and chronic application in patients with anal fissure 111
ESOPHAGEAL MOTILITY ASSESSMENT AFTER PRUCALOPRIDE ADMINISTRATION IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY (IEM) AND SYSTEMIC SCLEROSIS. 111
DISORDINI MOTORI ASPECIFICI DELL’ESOFAGO 109
TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS AND GASTRO-ESOPHAGEAL REFLUX EPISODES IN HEALTHY SUBJECTS AND GERD PATIENTS DURING 24 HOURS 109
RISPOSTA CLINICA E GUARIGIONE DELLA MUCOSA DOPO 4 ANNI DI TERAPIA CON INFLIXIMAB IN UN PAZIENTE CON MALATTIA DI CROHN ILEALE STEROIDO-RESISTENTE 108
Registrazione delle 24 ore della motilità del piloro in soggetti normali 107
EFFICACIA E SICUREZZA DEL RITRATTAMENTO CON INFLIXIMAB IN UN PAZIENTE AFFETTO DA MORBO DI CROHN 107
SHORT AND LONG TERM EFFICACY OF GLYCERYL TRINITRATE (GTN) OINTMENT 0.2% AND 2% ON ANAL CANAL PRESSURE IN PATIENTS WITH CHRONIC ANAL FISSURES. 107
EFFECT OF THE 5-HT3 RECEPTOR ANTAGONIST, ONDANSETRON, ON GASTRIC SIZE IN DYSPEPTIC PATIENTS WITH IMPAIRED GASTRIC ACCOMODATION 107
CLINICAL AND ECONOMIC EFFECT OF SHORT INFLIXIMAB INFUSION PROTOCOL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTRE STUDY 107
THERAPY- RELATED ADVERS EVENTS IN CROHN’S DISEASE (CD) – A COMPARISON BETWEEN THIOPURINES, INFLIXIMAB AND COMBINED THERAPY 106
Increase of swallows before the onset of phase III of migrating motor complex in normal human subjects 106
ULTRASOUND(US) GRADED HEPATOSTEATOSIS ASSESSMENT THROUGH CONTRAST ENHANCED ULTRASOUND (CEUS) AND FIBROSCAN IN NON ALCOHOLIC FATTY LIVER DISEASE 106
EFFECT OF CLEBOPRIDE ON ESOPHAGEAL MOTOR FUNCTION IN GERD PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY: EVALUATION USING HIGH RESOLUTION MANOMETRY 105
THERAPY-RELATED ADVERSE EVENTS IN CROHN’S DISEASE (CD) – A COMPARISON BETWEEN THIOPURINES, INFLIXIMAB AND COMBINED THERAPY 105
SPONTANEOUS OPENING OF LES IN ACHALASIA: AN UNCOMMON ON-LINE DOCUMENTATION BY HIGH-RESOLUTION MANOMETRY 105
FPSE-HPLC-PDA METHOD FOR THE DETERMINATION OF INFLAMMATORY BOWEL DISEASE TREATMENT DRUGS IN WHOLE BLOOD, PLASMA AND URINE 105
Proximal and Distal Gastric Distension in Normal Subjects and H. pylori-Positive and -Negative Dyspeptic Patients and Correlation with Symptoms 104
EFFECT OF AN ACUTE INTRALUMINAL ADMINISTRATION OF CAPSAICIN ON OESOPHAGEAL MOTOR PATTERN IN GORD PATIENTS WITH INEFFECTIVE OESOPHAGAL MOTILITY 104
I RILASCIAMENTI TRANSITORI DELLO SFINTERE ESOFAGEO INFERIORE NELLA GENESI DEI REFLUSSI GASTRO-ESOFAGEI: PROSPETTIVE TERAPEUTICHE 103
Role of nitric oxide on peristaltic motor activity in an in vitro rabbit intestinal preparation 103
REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMAMTORY BOWEL DISEASE (IG-IBD). 103
GRAVIDANZA IN UNA PAZIENTE AFFETTA DA RETTOCOLITE ULCEROSA IN TERAPIA CON INFLIXIMAB: CASO CLINICO 102
EFFECT OF HYOSCINE N-BUTYLBROMIDE ON GASTROESOPHAGEAL REFLUX IN NORMAL SUBJECTS AND PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE. 102
EFFECT OF THE 5-HT1 AGONIST SUMATRIPTAN ON ESOPHAGEAL MOTOR PATTERN IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY 102
Relationship between interdigestive esophageal and gastric motility in humans 102
Fabric Phase Sorptive Extraction-High Performance Liquid Chromatography-Photo Diode Array Detection Method for Simultaneous Monitoring of Three Inflammatory Bowel Disease Treatment Drugs in Whole Blood, Plasma and Urine 102
EVALUATION OF INTRA PARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND FIBROSIS BY FIBROSCAN IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON ALCOHOLIC STEATOHEPATITIS (NASH) AND COMPARISON WITH NORMAL CONTROLS 102
Gastric antral and fundic distention evaluated by ultrasonography (US) in normal subjects and patients with idiopathic dyspepsia 101
ON THE SPECIFICITY OF ALTERED MUSCLE FUNCTION IN EXPERIMENTAL COLITIS IN RATS 101
Effect of nitric oxide on propagated clusters of spontaneous motor waves in an ex vivo rabbit intestinal preparation 101
SAFETY OF INFLIXIMAB(IFX) ONE-HOUR INFUSION IN INFLAMMATORY BOWEL DISEASE(IBD): A MULTICENTER STUDY FROM SOUTHERN ITALY 101
Proximal and Distal Gastric Distension in Normal Subjects and H.pylori-Positive and -Negative Dyspeptic Patients and Correlation with Symptoms 100
LA MALDIGESTIONE 100
Relationship between interdigestive esophageal and gastric motility in humans 100
Totale 12.753
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.527
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.527
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202182 0 0 0 0 0 0 0 0 0 0 0 82
2021/2022789 35 15 4 200 46 16 24 66 54 9 88 232
2022/20232.154 188 207 108 264 194 488 145 158 253 41 59 49
2023/20241.002 79 51 62 36 34 292 236 37 14 44 19 98
2024/20252.576 182 423 292 47 54 66 99 173 310 121 252 557
2025/20265.394 488 252 637 543 453 328 787 407 577 430 424 68
Totale 18.963